相关实验视频

Updated: May 16, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

赛博隆通过SRSF1促进乳腺癌的化学敏感性

Chao Li^1,2, Lin Wang³, Zhaoyun Liu²

¹Shandong University Cancer Center, Jinan, Shandong, China.

Frontiers in pharmacology

|April 3, 2025

概括

赛博隆 (CYT) 通过抑制癌细胞生长和转移来对抗乳腺癌药物耐药性. 它的目标是SRSF1-调节的MYO1B剪接,提供了对抗抗性乳腺癌的新策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

乳腺癌是女性癌症相关死亡的主要原因之一.
SRSF1蛋白质影响拼接和癌症的进展.
赛博隆 (CYT) 对乳腺癌细胞表现出细胞毒性作用,但其对抗药物耐药性的机制尚不清楚.

研究的目的:

研究CYT对乳腺癌耐药性的影响.
探索CYT在耐药乳腺癌中的作用背后的分子机制.

主要方法:

在体外和体内对乳腺癌 (BC) 细胞的研究.
对表皮介质细胞转换 (EMT) 和癌症干细胞 (CSC) 生物标志物的分析.
转录组测序,RNA和SRSF1和MYO1B的蛋白质水平分析.
基因淘汰和过度表达的实验.

主要成果:

在不伤害正常细胞的情况下,CYT抑制了耐药BC细胞的生长,亡,迁移和入侵.
CYT治疗降低了SRSF1水平,并抑制了MYO1B的SRSF1调节的替代拼接,恢复了药物敏感性.
与单独使用CYT相比,联合CYT和多克索鲁比辛 (Dox) 治疗显示出更高的疗效.

结论:

通过向SRSF1-介导的MYO1B的替代拼接,CYT抑制了乳腺癌的生长和转移,并克服了耐药性.
这一途径代表了对抗耐药乳腺癌的新机制.
向SRSF1或MYO1B可能为耐药乳腺癌提供新的治疗策略.

关键词:

在EMT中,EMT是EMT.在SRSF1中,我们可以使用SRSF1.乳腺癌乳腺癌乳腺癌赛博隆多尼 (cyperotundone) 是一种药物耐药性耐药性药物耐药性

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...